Searchable abstracts of presentations at key conferences in endocrinology

ea0035p597 | Endocrine tumours and neoplasia | ECE2014

Everolimus in monotherapy as a therapeutic option in paragangliomas/pheochromocytomas

Cuadro Alberto Torres , Rodriguez Jose Perez , Tamarit Ana Albero , Hernandez Tomas Martin , Rivera Natividad Gonzalez , Zoilo Juan Jose Reina , Carrasco Fernando Henao , Merino Luis De La Cruz

Introduction: Everolimus is a drug selective inhibitor of mTOR. In 2012 a Phase 2 study* of everolimus monotherapy demonstrated modest efficacy in patients with pheochromocytomas/paragangliomas. Our objective was to evaluate the efficacy and safety of everolimus in a patient with paraganglioma. (*Phase 2 study of everolimus monotherapy in patient with nonfunctioning neuroendocrine tumor or pheochromocytomas/paraglangliomas. Do-Young Oh et al. Cancer 2012 <str...